Patient perception of generic antiepileptic drugs in the Midwestern United States

Epilepsy and Behavior

Volumn 14, Issue 1, 2009, Pages 150-153

  Papsdorf, Tania Beltran ^a   Ablah, Elizabeth ^a   Ram, Surya ^b   Sadler, Toni ^c   Liow, Kore ^a,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Neurophysiology Laboratory   (United States)

Author keywords

Antiepileptic drug; Brand; Epilepsy; Generic; Pharmacy; Seizure; Switch

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG;

ADULT; ARTICLE; AWARENESS; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; DRUG USE; HEALTH PERSONNEL ATTITUDE; HEALTH SURVEY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PERSONAL EXPERIENCE; PHARMACIST; SEIZURE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DATA COLLECTION; DRUGS, GENERIC; EPILEPSY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; KANSAS; MALE; MIDDLE AGED; MIDWESTERN UNITED STATES; PATIENT SATISFACTION; YOUNG ADULT;

EID: 58149259929     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.09.009     Document Type: Article

References (20)

1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Approved drug products with therapeutic equivalence evaluations (Orange Book) [database on the Internet]. 27th ed. 2006 January [updated 2008 Jan; cited 2008 Apr 7]. Available from: URL http://www.fda.gov/cder/ob/.
2. Snow D.B. Maximizing generic utilization: the power of pharmacy benefit management. J Gen Med 5 (2007) 27-38
3. Duh M.S., Andermann F., Paradis P.E., Weiner J., Manjunath R., and Cremieux P. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis Manage 10 (2007) 216-225
4. LeLorier J., Duh M.S., Paradis P.E., Latrémouille-Viau D., Lefebvre P., Manjunath R., et al. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin 24 (2008) 1069-1081
5. Kramer G., Biraben A., and Carreno M. Current approaches to the use of antiepileptic drugs. Epilepsy Behav 11 (2007) 46-52
6. Jobst B.C., and Holmes G.L. Prescribing antiepileptic drugs: should patients be switched on the basis of cost?. CNS Drugs 18 (2004) 617-628
7. Wilner A.N. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5 (2004) 995-998
8. Wilby J., Kainth A., Hawkins N., Epstein D., Mclntosh H., and McDaid C. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 9 15 (2005) 1-157
9. Crawford P., Hall W.W., Chappell B., Collings J., and Stewart II A. Generic prescribing for epilepsy: is it safe?. Seizure 5 (1996) 1-5
10. Crawford P., Feely M., Guberman A., and Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15 (2006) 165-176
11. Berg M.J., Gross R.A., Tomaszewski K.J., Zingaro W.M., and Haskins L.S. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 71 (2008) 525-530
12. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Bioavailability and bioequivalence studies for orally administered drug products-general considerations [online]. 2002 July [cited 2008 Apr 7]. Available from: URL: http://www.fda.gov/cder/guidance/4964dft.pdf.
13. Guberman A., and Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 27 (2000) 37-43
14. Haskins L.S., Tomaszweski K.J., and Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 7 (2005) 98-105
15. Wilner A.N. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav 3 (2002) 522-525
16. Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008; published ahead of print 10 September 2008.
17. Liow K., Barkley J.R., Pollard J.R., Harden C.L., and Bazil C.W. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 68 (2007) 1249-1250
18. Andermann F., Duh M.S., Gosselin A., and Paradis P.E. Cumpulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48 (2007) 464-469
19. Berg M. What's the problem with antiepileptic drugs? A call to action. Neurology 68 (2007) 1245-1246
20. Heaney D.C., and Sander J.W. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 6 (2007) 465-468